Advances in protein kinase B signalling: AKTion on multiple fronts.
By D. Brazil, Zhong-Zhou Yang, B. Hemmings. TIBS -Trends in Biochemical Sciences. Regular ed, 2004
894 citations recorded by the source corpus.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/85c03a17d1a5a4ee7691b94301643d26ac47e5fa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- J. Goldstein
- Douglas C. Wallace
- Michael S. Brown
- Michael N. Hall
- Marty C. Brandon
- Pierre Baldi
- W. Oppliger
- T. Force
Citations in the corpus
- Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition (2005, background): “Akt kinases control these activities by phosphorylation-mediated regulation of multiple substrates (for reviews see Brazil et al., 2004; Woodgett, 2005).”
- Mitochondrial mutations in cancer (2006, background): “The Akt kinases, in turn, mediate the signals of a variety of oncogenes (Aoki et al., 1998; Testa and Bellacosa, 2001; Brazil et al., 2004; Yanagihara et al., 2005).”
- Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis (2010, background): “The regulation of Akt is extremely complex, involving multiple phosphorylation sites and multiple interacting proteins (37).”
- Critical nodes in signalling pathways: insights into insulin action (2006, background): “AKT/PKB activity is regulated by several inhibitory molecules, including enzymes like the protein phosphatase-2A (PP2A) and the PH-domain leucine-rich repeat protein phosphatase (PHLPP), which directly dephosphorylate and deactivate AKT/PK”
- Protein kinase cascades in the regulation of cardiac hypertrophy. (2005, background): “(also known as PKB) and its activator, 3-phosphoinositide–dependent protein kinase–1 (PDK1), to the cell membrane via interactions between kinase pleckstrin homology domains and the 3′-phosphorylated lipid (Figure 1) (20).”
- Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions (2017, neutral): “For example, the AKT1_AKT2 and PIM1_PIM2 pairs are highly homologous kinase isoforms with known functional redundancy 36,37 and the BCL2L1_MCL1 and ATM_PRKDC pairs have similar biological functions (apoptosis and DNA damage repair, respectively).”
- In brief (2011, positive): “For mSIN1, mNIP7, Rpl7, Rps16, PTEN, or Bad knockdown, a pool of four different synthetic siRNA or of the appropriate control siRNA (Dharmacon) was used as described (Thedieck et al., 2007).”
- Perturbations of the AKT signaling pathway in human cancer (2005, background): “The biochemical mechanisms leading to AKT activation are well defined and have been recently reviewed in detail elsewhere (reviewed in Scheid and Woodgett, 2003; Brazil et al., 2004; Bellacosa et al., 2005).”